Michael J. Naslund, MD

EDUCATION:

            1973-1977:                              B.S. (1977) DavidsonCollege

                                                            Davidson, North Carolina

            1977-1981:                              M.D. (1981) The Johns Hopkins University

                                                            School of Medicine, Baltimore, Maryland

            1990-1992:                              M.B.A. (1992) The Wharton School of  Finance,

                                                            Philadelphia, Pennsylvania

RESIDENCY TRAINING:

            1981-1983                               General Surgery Residency

                                                            The JohnsHopkinsHospital

                                                            Baltimore, Maryland

            1983-1987                               Urology Residency

                                                            The JohnsHopkinsHospital

                                                            Baltimore, Maryland

I have clinical interests in benign prostatic enlargement (BPH) and prostate cancer.  I treat men who have urinary symptoms from an enlarged prostate with medication and , if needed, surgical procedures.  A multi-disciniplinary approach is used to mange men who have frequent urination at night. Minimally invasive options such as laser surgery are available.  Prostate cancer can be treated with robotic surgery, proton beam radiation or brachytherapy (seed radiation).  The treatment option offered is tailored to the needs of each individual patient.  In men with low grade, slow growing prostate cancer active surveillance is offered as an option to spare men the side effect risk of prostate cancer treatment.   Prostate mri scanning and mri based fusion prostate biopsies are available to improve the accuracy of prostate biopsies and to avoid unnecessary biopsies.  

benign prostatic hyperplasia, prostate cancer

Sausville, J. and Naslund, M.: Benign Prostatic Hyperplasia and Prostate Cancer: An Overview For Primary Care Physicians.  Int. J. Of Clinical Practice. 64: 1740, 2010.

Franklin, R., Zou, J., Zheng, Y., Naslund, M., and Costello, L.:Zinc Ionophore (Clioquinol) Inhibition of Human ZIP1-Deficient Prostate Tumor Growth in the Mouse Xenograft Model: A Zinc Approach for the Efficacious Treatment of Prostate Cancer.  Intl. Journal of Cancer and Clinical Research 2016, 3:037

Holt, CL,Saunders, DR, Wang, MQ, Slade, JL, Muwwakkil, B, Williams, R, Atkinson, NL, Whitehead, TL and Naslund, MJ. Informed Decision-Making and Satisfaction with a Church-Based Men’s Health Workshop Series for African-American Men:Men-Only vs. Mixed Gender Format. J. Cancer Educ. 2015: 30(3), 530-534.

Helfand, BT, , Lee JY, McVary KT; Naslund MJ, Sharp, V. Williams OD,   Harris,F. Associations between improvements in lower urinary tract symptoms and sleep disturbance over time in the CAMUS trial.   Journal of  Urology 2012;188(6):2288-93.

.      Barry MJ, Meleth S, Lee JY, Kreder KJ, Avins AL, Nickel JC, Roehrborn CG,     Crawford ED, Foster HE Jr, Kaplan SA, McCullough A, Andriole GL, Naslund            MJ, Williams OD, Kusek JW, Meyers CM, Betz JM, Cantor A, McVary KT; Complementary and Alternative Medicine for Urological Symptoms (CAMUS) Study Group. JAMA. 2011 Sep 28;306(12):1344-51.